NIMS Exer-Rest® Technology Linked to Reduced Brain Damage in Strokes

MIAMI--(BUSINESS WIRE)--Non-Invasive Monitoring Systems, Inc. [NIMS] (OTCBB:NIMU) announced today that the results of a laboratory investigation published in the April issue of the journal Neuroscience links the technology behind NIMS’ patented Exer-Rest® acceleration therapeutic platform to a reduction in brain damage for the major cause of stroke. In their report, “Whole-body periodic acceleration (pGz) reduces brain damage in a focal ischemia model,” Drs. Martinez-Murillo, Serrano, Fernandez and Martinez of CSIC and CIBIR, Madrid & Logroño, Spain concluded that whole body periodic acceleration (WBPA, pGz), the technology behind the Exer-Rest®, has potential to positively impact on the management of stroke, the third leading cause of death and the major cause of significant disability in adults living in the USA and Europe. They selected this treatment because it increases release of beneficial substances, such as nitric oxide, prostacyclin, prostaglandin E2, and adrenomedullin, from the inner lining of blood vessels into the circulation. These substances protect the brain from damage due to ischemia, i.e., cessation of blood flow to tissue. In their study, the investigators simulated occlusion of a brain blood vessel with clot, the cause of 85% of human strokes. In one group of rats, WBPA was administered for three hours immediately following the simulated stroke, while no treatment was provided to a control group. Magnetic resonance imaging (MRI) conducted 7 days after the simulated stroke revealed 82% less dead brain tissue in the WBPA-treated rats than in the untreated control group. In addition, biochemical markers of brain damage were significantly lower in the WBPA-treated animals.

Press release >> http://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20090401006091&newsLang=en